Answers are grounded in this paper and cite their sources.
ATP1A3 mutations should be considered in patients with paroxysmal non-epileptic neurological events which may show clinical overlap with paroxysmal non-kinesigenic dyskinesias.
No takes yet. Share an insight, caveat, or question.
Mark S. LeDoux (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: